The company has a licensing agreement with US listed Verrica Pharmaceuticals for treatment of basal cell carcinoma.

“Lytix is now a mature biotech company with a robust and promising portfolio of clinical studies in large cancer indications globally. This capital raise allows us to fast-track our lead drug candidate LTX-315 towards commercialization through a potential phase III study with our licensing partner Verrica, whilst at the same time bring our next generation molecule LTX-401 into clinical stage”, says Øystein Rekdal, CEO, Lytix Biopharma.

“We end 2024 on a high note”

“We are very happy having concluded a successful capital raise, with both strong support from existing shareholders, as well as bringing onboard new and solid investors. In addition, I am very happy to see the significant and increased interest from retail investors that participated in the offering through PrimaryBid and Nordnet. We end 2024 on a high note and look forward to progress our development into 2025, with several exciting milestones ahead,” says Rekdal.